Drug aims to wipe out lingering cancer after initial treatment
NCT ID NCT02649387
Summary
This study tested whether the drug ibrutinib could eliminate the last traces of cancer in patients with chronic lymphocytic leukemia (CLL) who had already responded to initial treatment but still had small amounts of disease left. Thirty-five patients took ibrutinib daily for up to three years to see if it could make them cancer-free in both blood and bone marrow tests. The main goal was to see how many patients achieved this 'no detectable cancer' status and how long it lasted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.